



About us

Deltamune, with a history dating back to 1977, is a Gauteng based South African company focusing on veterinary public health. Inactivated vaccines focusing on South African strains have been produced since 1980. The development of ELISA tests for various poultry diseases commenced in 1985. At Deltamune we support our customers to

achieve their production goals, backed by state of the art vaccines research and development, manufacture of biological products. Supported by an ISO 17025 (SANAS V.0007) accredited and Department of Agriculture, Forestry and Fisheries (DAFF) approved test laboratory.

Product Range and Capabilities

	Avian Influenza (AI)	E.coli	E.coli 0157	Egg Drop Syndrome (EDS)	Fowl Pox	Infectious Bronchitis (IB)	Infectious Bursal (IBD)	Infectious Coryza (COR)	M. gallisepticum (MIG)	Newcastle Disease (ND)	Ornithobacterium rhinotracheale (OR)	Pasteurella multocida (PM)	Pigeon Pox	Salmonella Enteritidis (SE)	Salmonella Gallinarum (SG)	Salmonella Infantis (SI)	Salmonella Muenchen (SM)	Salmonella Typhimurium (ST)	
Registered Products	AVIVAC® AI	X																	
	AVIVAC® COR/EDS			X				X											
	AVIVAC® CORYZA							X											
	AVIVAC® ND									X									
	AVIVAC® SE													X					
	STRUVAC ND PLUS									X									
	Autogenous vaccine solutions provided through veterinarians include:	X	X		X	X	X	X	X		X	X	X	X	X	X	X	X	X
	Vaccine support products																		

Contact us for solutions to your vaccination and laboratory needs

Email: info@deltamune.co.za Website: www.deltamune.co.za
 Telephone: +27 (0)12 664 5730 Fax: +27 (0)12 664 5149

Registration holder: DELTAMUNE (PTY) LTD Reg.1994/005981/07
 AVIVAC® AI is distributed by: Immuno-Vet Services CC (Reg. No. 1988/025418/23)
 Telephone: +27 (0)11 699-6240 Fax: +27 (0)11 462 0869
 Website: www.immunovet.co.za Email: info@immunovet.co.za



AVIVAC® AI

Reg. No. G 3747 Act 36/1947

The only available AI vaccine in South Africa

An oil-emulsion of inactivated avian influenza virus (H6N2 subtype) containing at least 1×10^8 EID₅₀ per dose (before inactivation)

1. Avian influenza is a controlled disease in terms of the Animal Diseases Act (Act 35/1984).
2. This vaccine against low pathogenic avian influenza (H6N2 subtype) may only be purchased subject to written permission obtained from the National Department of Agriculture by the veterinarian in charge of the health of the poultry flock





What is Avian Influenza?

Avian Influenza, H6N2 subtype, is an infectious viral disease of wild birds and poultry. It is readily spread by air currents, faeces, humans, vehicles, flies and infected flocks. Infection can occur via the digestive tract and by bird to bird contact. Some recovered birds remain carriers for several weeks. Clinical signs are usually classic respiratory involvement, listlessness, diarrhea. The acute form produces facial swelling, cyanosis and dehydration with respiratory distress and even increased mortality. Infections also result in a varying degree of egg production drops in layer and broiler breeder fowls. Wild birds and their excreta should be considered a major source of avian influenza. Preventing direct contact with free-flying birds and protecting domestic poultry from contact with the faeces of wild birds is an important way to prevent Avian Influenza.

In addition to effective immunisation with a suitable vaccine, strict biosecurity should be applied where known infections occur. Water from open water sources where waterfowl can contaminate the water should be treated to inactivate the virus to prevent outbreaks.

Development of this vaccine was done according to GLP guidelines and animal studies performed following GCP guidelines. Manufacturing of the vaccine is conducted in a facility that adheres to European GMP guidelines, with virus propagated in specific pathogen free (SPF) embryonated chicken eggs. Sterility testing is performed in the Deltamune ISO 17025 accredited laboratory (SANAS V.0007: VAC-QCD-ME-019 method).

Advantages of using AVIVAC® AI

- Vaccine virus derived from an outbreak of **low pathogenic H6N2 Avian Influenza in South Africa**
- **Maximum immunity** against homologous challenge
- High virus titre **increases immune response** against AI
- Oil adjuvated vaccine ensures **high immune response and long duration of immunity**
- **Increased safety and specificity** with viral antigen produced in specific pathogen free (SPF) eggs
- **World-class technical and laboratory support** for the product provided by Deltamune

AVIVAC® AI is indicated for preventive immunisation of healthy fowls against low pathogenic Avian Influenza (H6N2 subtype). The immunity induced should reach a maximum 4 weeks after the administration of the vaccine.

- **High immune response with HI titre $\geq 1 \times 10^6$**
- **All vaccine produced is tested for safety in chickens at double recommended dosage**
- **Maximum safety ensured during manufacturing process with in process sterility testing of antigen and final product**

Recommended dosage

A dose of 0,5 ml should be injected intramuscularly into the breast muscle of replacement pullets or breeding fowls older than 6 weeks of age. A booster dose of 0,5 ml should be administered after an interval of at least 4 weeks, but prior to lay.